CDK4 and breast carcinoma: After treatment with SKACP003, the CDK-4 and CDK-6 genes were significantly downregulated in the breast cancer cell lines compared to the control cell lines (Figure 2), indicating an anti-proliferative activity in all breast cancer cell lines tested.